中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Personalized Multi-Epitope Nanovaccine Unlocks B Cell-Mediated Multiple Pathways of Antitumor Immunity

文献类型：期刊论文

作者Yan, Wenlu2,3; Cao, Ying2,4; Xu, Shanshan5; Li, Yu2; Wu, Ting2,6; Yuan, Wenhui2,3; Yin, Qi2,3,5,7; Li, Yaping1,2,3,7
刊名ADVANCED MATERIALS
出版日期2024-12-23
页码19
关键词B lymphocytes cellular immunity humoral immunity nanovaccine tumor immunotherapy
ISSN号0935-9648
DOI10.1002/adma.202411361
通讯作者Yin, Qi(qyin@simm.ac.cn) ; Li, Yaping(ypli@simm.ac.cn)
英文摘要B lymphocytes have emerged as an important immune-regulating target. Inoculation with tumor cell membrane-derived vaccines is a promising strategy to activate B cells, yet their efficiency is limited due to lack of costimulatory molecules. To amplify B cell responses against tumor, herein, a spatiotemporally-synchronized antigen-adjuvant integrated nanovaccine, termed as CM-CpG-aCD40, is constructed by conjugating the immune stimulative CpG oligonucleotide and the anti-CD40 antibody (aCD40) onto the membrane vesicles derived from triple negative breast cancer cells. CM-CpG-aCD40 actively accumulates in lymph nodes and is effectively captured by antigen-presenting cells via the recognition of CD40 by aCD40. Tumor antigens on CM-CpG-aCD40 bind to B cell receptors, providing the first stimulation signal for B cells. Meanwhile, the interaction between CpG/Toll like receptor and aCD40/CD40 provides superposed co-stimulation signals, improving the antibody-secreting and antigen-presenting abilities of B cells. The nanovaccine also stimulates dendritic cells to activate CD8+ T cells, and reprograms tumor associated macrophages. CM-CpG-aCD40 activating humoral, cellular, and innate antitumor immunity achieves a tumor inhibition rate of 89.3%, which is further improved to 95.4% when combined with the anti-programmed death ligand 1 (PD-L1) antibody. CM-CpG-aCD40, as a personalized multi-epitope nanovaccine, paves the way for ushering the era of B cell-based immunotherapy.
WOS关键词CPG OLIGONUCLEOTIDES ; T-CELL ; CANCER ; IMMUNOTHERAPY ; VACCINES ; RESPONSES ; PATTERNS ; ANTIBODY
资助项目National Key R&D Program of China ; Shanghai Advanced Research Institute, Chinese Academy of Sciences, China ; National Natural Science Foundation of China[32130058] ; National Natural Science Foundation of China[32171315] ; National Natural Science Foundation of China[31930066] ; Natural Science Foundation of Shandong[ZR2019ZD25] ; Shandong Laboratory Program[SYS202205] ; [2022YFC3401404]
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种英语
WOS记录号WOS:001381609600001
出版者WILEY-V C H VERLAG GMBH
源URL[http://119.78.100.183/handle/2S10ELR8/315151]  
专题中国科学院上海药物研究所
通讯作者Yin, Qi; Li, Yaping
作者单位1.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264000, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res & Ctr Pharmaceut, Shanghai 201203, Peoples R China
3.Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China
4.Jilin Univ, Sch Life Sci, Changchun 130012, Peoples R China
5.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
6.Nanjing Med Univ, Sch Pharm, Dept Pharmaceut, Nanjing 211116, Peoples R China
7.Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Peoples R China
推荐引用方式
GB/T 7714		 Yan, Wenlu,Cao, Ying,Xu, Shanshan,et al. Personalized Multi-Epitope Nanovaccine Unlocks B Cell-Mediated Multiple Pathways of Antitumor Immunity[J]. ADVANCED MATERIALS,2024:19.
APA Yan, Wenlu.,Cao, Ying.,Xu, Shanshan.,Li, Yu.,Wu, Ting.,...&Li, Yaping.(2024).Personalized Multi-Epitope Nanovaccine Unlocks B Cell-Mediated Multiple Pathways of Antitumor Immunity.ADVANCED MATERIALS,19.
MLA Yan, Wenlu,et al."Personalized Multi-Epitope Nanovaccine Unlocks B Cell-Mediated Multiple Pathways of Antitumor Immunity".ADVANCED MATERIALS (2024):19.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。